Paul J.Marangos
A Roadmap for Curing CANCER,ALZHEIMER's And CARDIOVASCULAR DISEASE
"Terminal disease prematurely ends two million lives every year and is therefore the greatest tragedy we face today.The mission of Biomedica Partners is to cure terminal diseases by reforming health care policy."
BIO
Dr. Marangos is author of 252 peer-reviewed research papers on neurobiology with an emphasis on new drug development for neurodegenerative diseases, and 4 books – three by Academic Press (the Neurobiological Research series of volumes)and a fourth titled“Emerging strategies in Neuroprotection”. He is a founding editor of “The Journal of Molecular Neuroscience” and inventor on 14 issued patents.
He spent 13 years at the NIH and was adjunct professor of neurochemistry at George Washington School of Medicine during that time as well.
He is co-Founder of five Biotech firms over 30 years with extensive experience in all aspects of the pharmaceutical and biotechnology industries from bench to product.
He has raised over $100 million in equity capital and led several M/A transactions and numerous licensing deals.
This coupled with his academic experience has provided a global perspective on the entire medical R&D enterprise, its faults, and remedies to speed the quest for cures, all of which are presented in the current book.
Call To Action
There is much to do to enable medical R&D in the task of curing terminal diseases. The first step is to raise awareness and plot a course. The book has started that. The next step is to get something done and that is to pass the proposed Terminal Disease Act (TDA). I am considering a March on Washington to accomplish this. This would be the first such march that speaks for every citizen and not just a special interest group. I ask anyone concerned about terminal disease to contact us regarding how to assist in this effort.
Paul J Marangos
CEO, Biomedica partner LLC
Press/Media Release
-
https://www.wsj.com/articles/the-terminally-ill-need-more-than-the-right-to-try-1534200199.
-
The TDA is the transformational change required to finally cure terminal disease. It goes far beyond the "Right to Try" initiative currently before Congress which is silent on reforms to speed new approved treatment options for terminal patients," stated Paul J. Marangos, founder and CEO of Biomedica Partners. Click here to read complete press release
-
Since the passage of the Affordable Care Act in 2010, healthcare has become a lot less affordable, and Washington has now essentially admitted defeat in trying to fix it. But we are fighting the wrong battle. Click here to read further
-
https://www.wsj.com/articles/the-right-to-try-bill-wasnt-worth-passing-1528126185
CONTACT
For any inquiries, please contact : Dr Paul J. Marangos
Follow me: